This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasingknowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively. INDICE: Preface.- Dopaminergic dysfunction in psychotic disorders.- Role of dopamine D2 receptors for antipsychotic activity.- Dopamine receptor signaling pathways and antipsychotics.- Serotonergic mechanisms as targets for existing and novel antipsychotics.- Antipsychotics in the treatment of psychoses during development.- Weight gain and metabolic disturbances induced by antipsychotic treatments.- Medical needs in the treatment of psychotic disorders.- Antipsychotics in the treatment of bipolar disorders.- Pharmacogenomics of antipsychotics.- Drug interactions and drug monitoting of antipsychotics.- Delivery systems and dosing for antipsychotics.- Imaging as tool to investigate psychosesand antipsychotics.- Biomarkers for antipsychotic therapies.- Behavioral animal models of antipsychotic drug actions
- ISBN: 978-3-642-25760-5
- Editorial: Springer
- Encuadernacion: Cartoné
- Fecha Publicación: 30/09/2012
- Nº Volúmenes: 1
- Idioma: Inglés